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Visual Abstract
Mutations in the leucine-rich repeat kinase 2 (LRRK2)
gene have been identified as an unambiguous cause of
late-onset, autosomal-dominant familial Parkinson’s dis-
ease (PD) and LRRK2 mutations are the strongest genetic
risk factor for sporadic PD known to date. A number of
transgenic mice expressing wild-type or mutant LRRK2
have been described with varying degrees of LRRK2-
related abnormalities and modest pathologies. None of
these studies directly addressed the role of the kinase
domain in the changes observed and none of the mice
present with robust features of the human disease.
In an attempt to address these issues, we created a
conditional LRRK2 G2019S (LRRK2 GS) mutant and a
functionally negative control, LRRK2 G2019S/D1994A
(LRRK2 GS/DA). Expression of LRRK2 GS or LRRK2
Significance Statement
Mutations in leucine-rich repeat kinase 2 (LRRK2) gene are the most common genetic cause for both familial and
sporadic Parkinson’s disease to date with the G2019S LRRK2 (LRRK2 GS) being the most prevalent mutation. The
clinical presentation of patients carrying LRRK2 GS is indistinguishable from sporadic disease in many cases. Many
lines of evidence indicate that LRRK2 GS has increased kinase activity and that in vitro LRRK2 inhibitors or
kinase-dead G2019S/D1994A double mutants (LRRK2 GS/DA) reduce LRRK2 GS-mediated toxicity, indicating that
LRRK2 associated toxicity is kinase dependent. However, this concept remains controversial. To address this
question in vivo, we developed a new tet-inducible conditional transgenic LRRK2 GS and LRRK2 GS/DA mouse
model, which exhibits behavioral deficits and -synuclein pathology in a kinase-dependent manner.
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GS/DA was conditionally controlled using the tet-off system in which the presence of tetracycline-transactivator
protein (tTA) with a CAMKII promoter (CAMKII-tTA) induced expression of TetP-LRRK2 GS or TetP-LRRK2
GS/DA in the mouse forebrain. Overexpression of LRRK2 GS in mouse forebrain induced behavioral deficits and
-synuclein pathology in a kinase-dependent manner. Similar to other genetically engineered LRRK2 GS mice,
there was no significant loss of dopaminergic neurons. These mice provide an important new tool to study
neurobiological changes associated with the increased kinase activity from the LRRK2 G2019S mutation, which
may ultimately lead to a better understanding of not only the physiologic actions of LRRK2, but also potential
pathologic actions that underlie LRRK2 GS-associated PD.
Key words: Parkinson’s disease; LRRK2; transgenic mice; -synuclein
Introduction
Parkinson’s disease (PD) is recognized as the most
common movement disorder. The cardinal symptoms are
caused by the progressive degeneration of dopaminergic
(DA) neurons in the substantia nigra pars compacta
(SNpc; Lees et al., 2009). Mutations in the leucine-rich
repeat kinase 2 (LRRK2) gene have been linked to both
familial and sporadic forms of PD (Paisán-Ruíz et al.,
2004; Zimprich et al., 2004). The LRRK2 protein contains
two enzymatic domains (GTPase and kinase domains)
and multiple protein–protein interacting domains includ-
ing an LRR, a WD40 repeat, and a LRRK2-specific repeat
domain (Mata et al., 2006; Cookson, 2010). The G2019S
(GS) mutation within the kinase domain is the most com-
mon mutation of LRRK2, which alters LRRK2 GTPase and
kinase activities (Lees et al., 2009; Martin et al., 2014b).
LRRK2 GS mutations lead to alterations in vesicle traffick-
ing, neurite outgrowth, autophagy, cytoskeletal dynamics
in vitro (Martin et al., 2014b; Cookson, 2015), as well as
defects in protein translation both in vitro and in vivo (Imai
et al., 2008; Gehrke et al., 2010; Dorval and Hébert, 2012;
Martin et al., 2014a,b,c). To study the function of LRRK2
and potential pathologic actions of LRRK2 mutations,
many lines of transgenic (Tg) or knock-in mice have been
generated. These animal models have provided interest-
ing and valuable biochemical and physiologic insights,
but none of these models have recapitulated key features
of PD (Li et al., 2009, 2010; Lin et al., 2009; Tong et al.,
2009; Melrose et al., 2010; Herzig et al., 2011; Ramonet
et al., 2011; Chen et al., 2012; Tsika et al., 2014; Beccano-
Kelly et al., 2015; Garcia-Miralles et al., 2015; Liu et al.,
2015; Volta et al., 2015; Yue et al., 2015; Weng et al.,
2016). Interestingly, no animal models have been created
to directly test the role of increased kinase activity with
the common LRRK2 GS mutation. To address this, we
developed a new Tet-inducible conditional LRRK2 mutant
G2019S (TetP-LRRK2 GS) transgenic mouse line and a
corresponding functionally negative control G2019S/
D1994A (TetP-LRRK2 GS/DA) mouse line under the con-
trol of a tetracycline-responsive regulator. Crossbreeding
the TetP-LRRK2 GS or TetP-LRRK2 GS/DA mice to
CamKII-tTA mice (Mayford et al., 1996) led to high ex-
pression levels of LRRK2 GS or the control LRRK2 GS/DA
in adult mouse forebrain. High expression of LRRK2 GS
induces behavioral deficits and -synuclein pathology but
does not cause significant dopamine neurodegeneration.
Nevertheless, these novel transgenic mice offer an excel-
lent platform to explore and elucidate the kinase-
dependent actions of LRRK2 in the brain.
Materials and Methods
Animals
Mice were housed and treated in accordance with the
National Institutes of Health (NIH) Guide for the Care and
Use of Laboratory Animals and Institutional Animal Care
and Use Committees. Animals were housed in a 12 h
dark/light cycle with free access to water and food. Both
male and female animals were assigned to groups by
computer-generated randomization for all experiments.
Mice were acclimatized for 3 d in the procedure room
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before any experiments were started. Sample size was
justified by power analysis.
Generation of conditional LRRK2 transgenic mouse
A tandem affinity purification (TAP) tag composed of the
streptavidin-binding peptide and calmodulin-binding pep-
tide was cloned into C-terminal human LRRK2 GS or a
LRRK2 GS/DA under the control of a tetracycline respon-
sive regulator (Fig. 1A). The transgenic constructs were
linearized by the NotI enzyme and subsequently microin-
jected into the embryos of B6C3F2 mice. One- or two-cell
embryos were transferred into B6D2F1 pseudopregnant
female mice. Genomic DNA was prepared from tail snip
(Proteinase K, Roche Diagnostics; direct PCR tail Lysis,
Viagen), and pups were genotyped by PCR (DreamTaq
Green Master Mix, Thermo Scientific) using TetP-LRRK2
primers (forward, CGG GTC GAG TAG GCG TGT AC;
reverse, TCT AGA TGA TCC CCG GGT ACC GAG; PCR
product  173 bp). Positive founders were selected and
further subjected to semiquantitative PCR and normalized
to GAPDH PCR (forward, AAA CCC ATC ACC ATC TTC
CAG; reverse, AGG GGC CAT CCA CAG TCT TCT; PCR
product 300 bp) to screen for high-copy number found-
ers. The three highest copy number founders were se-
lected and bred with C57BL/6 mice to generate F1
progeny and to establish the transgenic lines. The follow-
ing primer sets were used for genotyping of CamKII-tTA
(forward, TGA AAG TGG GTC CGC GTA C; reverse, TAC
TCG TCA ATT CCA AGG GC; PCR product  391 bp).
LRRK2 induction in conditional transgenic mice was sup-
pressed by feeding the mice with doxycycline-containing
food (doxycycline Diet-Sterile, 200 mg/kg doxycycline,
Bio-Serv).
Stereological assessment of the number of tyrosine
hydroxylase- and Nissl-positive cells
Mice were perfused with ice-cold PBS, followed by 4%
paraformaldehyde/PBS, pH 7.4. Brains were removed
and postfixed overnight in the same fixative. After cryo-
protection in 30% sucrose/PBS, brains were frozen on dry
ice, and serial coronal sections (40 m sections) were cut
with a microtome. Every four sections were collected
for subsequent procedures. Free-floating sections were
blocked with 4% goat serum (Sigma-Aldrich)/PBS plus
0.3% Triton X-100 and incubated with antibodies to ty-
rosine hydroxylase (TH; rabbit polyclonal; Novus Biologi-
cals; RRID:AB_1218296) followed by incubation with
biotin-conjugated antibody to rabbit, ABC reagents (Vec-
tor Laboratories) and Sigmafast diaminobenzidine tablets
(Sigma-Aldrich). Sections were counterstained with Nissl
(0.09% thionin) after tyrosine hydroxylase staining, as
previously described (Lee et al., 2013; Karuppagounder
et al., 2016). Sections were dehydrated in 100% ethanol
and cleared in xylene (Fisher Scientific) followed by
mounting with DPX (Sigma-Aldrich) before imaging under
a microscope. TH-positive and Nissl-positive DA neurons
from the SNpc region were counted through an optical
fractionator, the unbiased method for cell counting. This
unbiased stereological counting was conducted by a
computer-assisted image analysis system consisting
of an Axiophot photomicroscope (Carl Zeiss Vision)
equipped with a computer-controlled motorized stage
(Ludl Electronics), a Hitachi HV C20 video camera and
Stereo Investigator software (MicroBrightField). Fiber
density in the striatum was quantified by optical density
(OD). ImageJ software (NIH) was used to analyze the OD
as previously described (Karuppagounder et al., 2016).
Western blotting
Brain extracts from indicated genotype were prepared
by homogenization in lysis buffer [1 phosphate-buffered
saline, 1% Triton X-100, 1 Complete protease inhibitor
(4693116001, Sigma-Aldrich), 1 PhosSTOP phospha-
tase inhibitor (4906845001; Sigma-Aldrich)]. Protein con-
centration was determined by the BCA method (Pierce
Biotechnology). Approximately 100 g of protein was
resolved by SDS-PAGE, transferred to polyvinylidene flu-
oride membrane and probed with mouse anti-LRRK2 an-
tibody (N136/8, NeuroMab; RRID:AB_2234791) or rabbit
anti-LRRK2 antibody (1304; D18E12, Cell Signaling Tech-
nology) recognizing both mouse and human LRRK2.
Membranes were also probed with rabbit anti-LRRK2
phospho Ser1292 antibody (ab203181; MJFR-19-7-8,
Abcam), mouse anti--synuclein antibody (610787; BD
Transduction Laboratories; RRID:AB_398108), rabbit anti-
-synuclein antibody (2642; Cell Signaling Technology;
RRID:AB_2192679), anti-actin-peroxidase rabbit poly-
clonal antibody for loading control (A3854; Sigma-Aldrich;
RRID:AB_262011). Densitometric analysis was conducted
to quantify the fold overexpression of LRRK2 relative to
endogenous mouse LRRK2. Total LRRK2 protein levels
were normalized to actin and expressed as the percent-
age of non-Tg controls. Mean values from three mice per
genotype/control were analyzed for statistical significance
by two-tailed unpaired Student’s t test compared with
non-Tg controls.
Open field test and d-amphetamine administration
Spontaneous locomotor and exploratory activities were
assessed in open field square-shaped (16  16) cham-
bers equipped with an automated photobeam tracking
system (San Diego Instruments). Briefly, a mouse was
placed in the center of the open field arena and allowed to
explore the area for 25 min, following by D-amphetamine
injection (7 mg/kg, s.c.; A-5880, lot #34H0145, Sigma-
Aldrich) and another 25 min exploration. The activities of a
mouse were recorded every minute by Photobeam Activ-
ity System software installed on a computer connected to
the open field equipment. Before and after each testing,
the clear acrylic enclosure of the surface of the arena was
cleaned with 70% ethanol. The total number of beam
breaks during the total 50 min period was used to deter-
mine gross locomotor activity of a mouse.
Rotarod test
Motor coordination of mice was measured as the re-
tention time on an accelerating rotarod of the rotamex V
instrument equipped with photobeams and a sensor to
automatically detect mice that fell from the rotarod (Co-
lumbus Instruments). Before the actual test, the mice
were trained on the rotarod at 4.0–40 rpm for 5 min and
allowed to rest for at least 30 min. The training occurred
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Figure 1. Generation of TET-inducible conditional LRRK2 transgenic mice. A, Schematic diagram of the TetP-LRRK2-TAP construct.
B, Relative transgene copy number determined by semiquantitative PCR performed on genomic DNA expressed in arbitrary units as
the ratio of the TetP-LRRK2-G2019S (GS) transgene to GAPDH for each founder mouse. C, Relative transgene copy number
determined by semiquantitative PCR performed on genomic DNA expressed in arbitrary units as the ratio of the TetP-LRRK2-
GS2019S/D1994A (GS/DA) transgene to GAPDH for each founder mouse. D, Schematic diagram of the generation of LRRK2-
inducible transgenic mice using the “tet-off” system. E, Representative genotyping PCR for TetP-LRRK2 and CamKII-tTA using
genomic DNA. GAPDH PCR was used as an internal control. F, Western blot analysis of LRRK2 expression from LRRK2 transgenic
mouse brain. Each number represents a single LRRK2 transgenic founder line: 569, 648 and 597 of LRRK2-GS, 767, 763, and 768
LRRK2-GS/DA transgenic mice. G, Quantification of LRRK2 expression in mouse brains normalized to -actin, n  3. Differences
between transgenic and control groups were assessed by unpaired, two-tailed Student’s t test. Quantified data are expressed as the
mean  SEM. p  0.05, p  0.001. H, Representative Western blots of LRRK2 distribution in brain subregions from control and
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over 3 consecutive days and consists of three test trials.
On the day of the test, four mice were placed on separate
rods and the durations on the accelerating rods were
recorded automatically by the software installed on a
computer connected to the instrument. The setting of the
rotamex was as follows: start speed, 4.0 rpm; maximum
speed, 40 rpm; acceleration interval, 30 s; acceleration
step, 4 rpm. The setting remained constant throughout all
trials. The tests were blinded and evaluated in three ses-
sions, and the average retention time and end speed were
recorded for each mouse. The retention time was used to
determine the motor coordination of the mouse.
Pole test
The pole consists of a 2.5 foot metal rod with a 9 mm
diameter that is wrapped with bandage gauze. Briefly, the
mice were placed 3 inches from the top of the pole facing
head-up. Total time taken to turn and reach the base of
the pole was recorded. Before the actual test, the mice
were trained for 3 consecutive days, and each training
session consisted of three test trials. On the day of the
test, mice were evaluated in three sessions with 1 h
intervals in between, and total times were recorded. Re-
sults were expressed in total time in seconds (Karuppa-
gounder et al., 2016)
Statistical analysis
Two-way ANOVA and two-tailed unpaired Student’s t
test was used for data analysis. Data represent the mean
 SEM, and p  0.05 was considered statistically signif-
icant: p  0.05, p  0.01, p  0.001. Power
analysis was performed by using GPower 3.1 software to
determine approximate sample sizes for behavior tests or
stereological analysis.
Results
Generation of TET-inducible conditional LRRK2
transgenic mice
We generated tetracycline responsive transgenic mice
(TetP-LRRK2 GS or TetP-LRRK2 GS/DA) using C-terminal
TAP tagged human LRRK2 GS or LRRK2 GS/DA under
the control of a tetracycline responsive regulator (Fig. 1A).
Twenty-seven TetP-LRRK2 GS founders and 33 TetP-
LRRK2 GS/DA founder mice were identified by PCR
screening for the tetracycline promoter (Fig. 1B,C). Three
male mice with the highest copy number were selected as
founders and crossbred to CamKII -tTA transgenic mice
(Mayford et al., 1996; Fig. 1D). Dams were maintained on
doxycycline food until pups were weaned to prevent ex-
pression of transgenes and possible compensation during
development. Mice expressing both CamKII -tTA and
TetP-LRRK2 GS or TetP-LRRK2 GS/DA were identified
by PCR (Fig. 1E). At 2 months of age, doxycycline food
was withdrawn and the overexpression of LRRK2 GS or
LRRK2 GS/DA was monitored. LRRK2 GS is overex-
pressed 16-, 5-, and 2-fold in lines 569, 648, and 597,
respectively, and LRRK2 GS/DA is overexpressed 6-, 15-,
3-fold in lines 767, 763, and 768, respectively (Fig. 1F,G).
Since line 569 and line 763 overexpress LRRK2 at similar
levels, they were selected for further study. A regional
assessment of the overexpression of LRRK2 GS (line 569)
and LRRK2 GS/DA (line 763) were monitored by Western
blot analysis (Fig. 1H,I). LRRK2 GS or GS/DA is overex-
pressed 5-, 15-, 17-, 9-, and 4-fold in the olfactory bulb
(OB), cortex (CTX), striatum (STR), hippocampus (HIP),
and ventral midbrain (VMB), respectively, while there is no
significant change in LRRK2 expression in the brainstem
(BS), and cerebellum (CER; Fig. 1H,I). Collectively, LRRK2
was induced at very high levels in the mouse forebrain. To
monitor LRRK2 kinase activity and confirm that LRRK2
GS/DA is kinase dead in vivo, the phosphorylation status
of LRRK2 was examined in LRRK2 GS and LRRK2 GS/DA
mice by LRRK2 phosphor S1292 antibody (Fig. 1J,K).
Western blots of total protein from mouse brains of con-
trol, LRRK2 GS, and LRRK2 GS/DA revealed that LRRK2
GS has a high phosphorylation level and LRRK2 GS/DA
does not have a detectable kinase activity (Fig. 1J,K).
Behavioral deficits of conditional LRRK2-G2019S
transgenic mice
The potential effects of LRRK2 GS expression on motor
behavior were assessed. Open field, pole, and rotarod
testing were performed with LRRK2 GS and LRRK2
GS/DA transgenic mice. LRRK2 GS and LRRK2 GS/DA
transgenic mice performed similarly as nontransgenic
control mice under normal conditions in the open field test
at 10, 15, and 22 months of age (Fig. 2A; data not shown).
There was no significant difference between LRRK2 GS
and LRRK2 GS/DA at 10 and 15 months of age (data not
shown). Interestingly, LRRK2 GS mice have a blunted
response to D-amphetamine administration (7 mg/kg, s.c.)
at 22 months, whereas nontransgenic and LRRK2 GS/DA
mice exhibit increased activity (Fig. 2A). In the dopamine-
sensitive pole test assessed at 22 months of age, LRRK2
GS transgenic mice had an insignificant deficit in ability to
descend the pole (p  0.0514). The LRRK2 GS/DA per-
formed similar to nontransgenic control mice (Fig. 2B). In
the rotarod test, both the LRRK2 GS and LRRK2 GS/DA
transgenic mice performed normally at 10, 15, and 22
months of age (Fig. 2C; data not shown). Together, these
results indicate that the LRRK2 GS mice have no robust
DA-sensitive behavioral deficits.
continued
LRRK2-GS (line 569) and LRRK2-GS/DA (line 763) transgenic mice (OB; CTX; STR; HIP; VMB; BS; CER). I, Quantification of LRRK2
distribution in mouse brains normalized to -actin, n 3. J, Western blot analysis of total protein frommouse brains of control, LRRK2
GS, and LRRK2 GS/DA by anti-LRRK2 and LRRK2 phosphor S1292 antibodies. K, Quantification of phosphor Ser1292 LRRK2 levels
in mouse brains normalized to total LRRK2 protein level, n  3. Quantified data are expressed as the mean  SEM: p  0.05, p
 0.01, p  0.001, Differences between transgenic and control groups were assessed by two-way ANOVA. There was a
nonsignificant difference between LRRK2 GS and LRRK2 GS/DA groups.
New Research 5 of 10
March/April 2017, 4(2) e0004-17.2017 eNeuro.org
Conditional LRRK2-G2019S transgenic mice exhibit
normal nigrostriatal dopaminergic pathway
To determine whether temporal overexpression of
LRRK2 GS in the mouse forebrain induces the degener-
ation of midbrain DA neurons, we assessed DA neuronal
number by unbiased stereological counting of TH- and
Nissl-positive neurons at 22 months of age. No significant
DA neuronal loss was observed (Fig. 3A–C). Dopaminer-
gic neurons are of normal size and morphology in the
substantia nigra of LRRK2 GS mice (Fig. 3A). The fiber
density of TH-positive dopaminergic nerve terminals in
the striatum are unaltered in LRRK2 GS mice at 22
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Figure 2. Behavioral deficits of conditional LRRK2-G2019S
transgenic mice. A, Open field analysis under normal conditions
and following amphetamine challenge. Mice were placed in the
center of the open field arena and allowed to explore the area for
25 min, following by D-amphetamine injection (7 mg/kg, s.c.) and
another 25 min exploration. The total activities of mice were
recorded every minute (control, n 7; GS, n 9; GS/DA, n 8).
B, Pole test to monitor the behavioral abnormalities of 22-month-
old LRRK2 GS and GSDA transgenic and age-matched litter-
mate controls (control, n  8; GS, n  8; GS/DA, n  7). C,
Assessment of latency to fall in an accelerated rotarod test
(control, n  8; GS, n  9; GS/DA, n  8). Data are the mean 
SEM. Statistical significance was determined by two-way
ANOVA. p  0.05. n.s., Nonsignificant.
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Figure 3. Characterization of the nigrostriatal pathway of LRRK2
conditional transgenic mice. A, Representative TH immunohisto-
chemistry of the midbrain coronal sections of 22-month-old LRRK2
GS and GSDA transgenic and age-matched littermate controls. B,
C, Stereological assessment of TH-positive (B) and Nissl-positive
(C) neurons in the SNpc (control, n  9; GS, n  9; GS/DA, n  9).
Data are the mean number of cells per region  SEM, n  9 mice
per group. Statistical significance was determined by two-tailed
unpaired Student’s t test. D, Representative images of TH immu-
nostaining of nerve terminals in the striatum of LRRK2 conditional
transgenic mice at 22 months of age. E, Quantitation of TH immu-
nostaining in the striatum using ImageJ software (NIH; control, n 
7; GS, n  7; GS/DA, n  7). Differences between groups were
assessed by two-way ANOVA. Bars represent the mean  SEM (n
 5 animals/genotype). n.s., Nonsignificant.
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Figure 4. The levels of -synuclein aggregation in the LRRK2 GS and LRRK2 GSDA mice. A, Representative immunoblots of
-synuclein and -actin in the Triton X-100 (TX)-soluble fraction of different brain regions from 22-month-old transgenic mice and
age-matched littermate non-Tg controls. B, Representative immunoblots of -synuclein and -actin in the TX-insoluble fraction of
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months of age (Fig. 3D,E). Together, our data suggest that
the high levels of expression of LRRK2 GS in mouse
forebrain are not sufficient to induce the degeneration of
dopaminergic neurons of the nigrostriatal dopaminergic
pathway with advancing age. These findings are consis-
tent with the behavioral data.
-Synuclein pathology in conditional LRRK2-G2019S
transgenic mice
Since the majority of patients carrying the LRRK2 GS
mutation have -synuclein positive Lewy bodies and
increased levels of phospho-serine 129 (pS129) -synuc-
lein, the status of endogenous -synuclein was monitored
in the nontransgenic control, LRRK2 GS, and LRRK2
GS/DA mice. Immunoblot analysis for -synuclein in the
Triton X-100-soluble fraction reveals no substantial differ-
ence in the immunoreactivity for -synuclein (Fig. 4A) and
no detectable immunoreactivity for pS129 -synuclein
(data not shown) at 22 months between LRRK2 GS mice
and LRRK2 GS/DA mice. In the Triton X-100-insoluble
fraction, the observed high-molecular-weight species
(75 kDa) of -synuclein are indicative of aggregation and
are similar between LRRK2 GS and LRRK2 GS/DA mice in
the VMB, BS, and CER regions but are significantly in-
creased in the OB, CTX, STR, and HIP of LRRK2 GS mice
at 22 months of age compared with LRRK2 GS/DA and
non-Tg control mice (Fig. 4B,C). Moreover, in the Triton
X-100-insoluble fraction, low and similar levels of immu-
noreactivity for pS129 -synuclein are observed in STR,
VMB, BS, and CER brain regions of non-Tg, LRRK2 GS,
and LRRK2 GS/DA mice. In contrast, pS129 -synuclein
levels are significantly increased in OB, CTX, and HIP
brain regions of 22-month-old LRRK2 GS mice compared
with LRRK2 GS/DA and non-Tg control mice of the same
age (Fig. 4B,D). No significant difference in the immuno-
reactivity for -synuclein and pS129 -synuclein in both
Triton X-100-soluble and insoluble fractions was ob-
served at the ages of 10 and 15 months among LRRK2
GS, GS/DA, and non-Tg control mice (data not shown).
This observation suggests that the LRRK2 GS mutation
can promote -synuclein pathology in a kinase- and age-
dependent manner.
Discussion
It is well established that the disease causing LRRK2
GS mutation exhibits increased kinase activity for both
autophosphorylation and hyperphosphorylation of LRRK2
kinase substrates, while LRRK2 kinase inhibitors or ki-
nase-dead G2019S/D1994A double mutants reduce
LRRK2 GS-mediated toxicity indicating that LRRK2 tox-
icity is kinase dependent (Martin et al., 2014b; Cookson,
2015). This conclusion remains controversial, and alterna-
tive hypotheses have been suggested (Skibinski et al.,
2014). To define the kinase-dependent and kinase-in-
dependent pathophysiologic actions of LRRK2, additional
models are needed. Thus, we generated a conditional
tet-off LRRK2 G2019S (LRRK2 GS) mutant and a func-
tionally negative control, LRRK2 G2019S/D1994A (LRRK2
GS/DA), driven by the CAMKII promoter. Overexpres-
sion of LRRK2 GS in mouse forebrain induced behavioral
deficits and -synuclein pathology in a kinase-dependent
manner, whereas these events were absent in the LRRK2
GS/DA mice. However, consistent with other genetically
engineered LRRK2 GS mice, there was no significant loss
of dopaminergic neurons.
Since the majority of LRRK2 PD patients exhibit -
synuclein aggregation, the role of LRRK2 in -synuclein
pathology in different LRRK2 mouse models has been
explored. Lin et al. (2009) showed that overexpression of
LRRK2 in mouse forebrain promotes the abnormal aggre-
gation of exogenously overexpressed -synuclein and
knockout of LRRK2-rescued A53T -synuclein overex-
pression-induced abnormalities. However, Tong et al.
(2010) demonstrated that LRRK2 knock-out mice present
with a robust aggregation of -synuclein, while Daher
et al. (2012) showed that knockout of LRRK2 has no
influence on A53T -synuclein-induced neurodegenera-
tion. The different findings between these studies could
be due to the different -synuclein expression levels or
technical concerns. Our LRRK2 mouse model provides
the first evidence that the overexpression of LRRK2 in
mouse forebrain induces endogenous -synuclein aggre-
gation and increased pS129 -synuclein levels, which
occur in a kinase-dependent manner. Whether LRRK2
could be used as a therapeutic target for -synuclein-
mediated neurodegeneration remains to be elucidated.
The reasons why past rodent models of the LRRK2 GS
mutation as well as our new transgenic mouse model do
not exhibit nigral neurodegeneration is not known, al-
though many -synuclein-based mouse models also lack
nigral neurodegeneration (Lee, et al., 2012). Possibilities
include compensatory mechanisms, levels of expression
that are higher in brain regions other than the ventral
midbrain or substantia nigra, poor expression in the sub-
stantia nigra, or lack of expression of the LRRK2 GS
mutation in cell types other than neurons such as astro-
cytes or microglia.
All of these possibilities should be taken into consider-
ation in developing new LRRK2 animal models meant to
study neurodegeneration. The lack of neurodegeneration
does not diminish the value of these models for biochem-
continued
different brain regions from 22-month-old transgenic mice and age-matched littermate non-Tg controls. In the insoluble fractions,
high-molecular-weight (75 kDa) species of -synuclein are detected in OB, CTX, STR, and HIP but not in VMB, BS, and CER of LRRK2
GS mice. C, Quantification of high-molecular-weight (HMW) -synuclein protein levels in B normalized to -actin (control, n  3; GS,
n  3; GS/DA, n  3). D, Quantification of pS129 -synuclein protein levels in B normalized to -synuclease monomer (17 kDa;
control, n  3; GS, n  3; GS/DA, n  3). Differences between LRRK2 GS and the control or LRRK2 GS/DA group were assessed
by two-way ANOVA. Bars represent the mean  SEM. p  0.05, p  0.01, p  0.001. There was a nonsignificant difference
between LRRK2 GS/DA and control groups.
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ical investigations of the function of LRRK2. When cou-
pled with the ability to purify the LRRK2 protein complex
via the TAP tag, our new mouse model permits the inves-
tigation of increased kinase activity on LRRK2 biologic
substrates and outcomes. Overall, these mice provide an
important new tool to study neurobiologic changes that
are due to the overactivation of the kinase activity by the
LRRK2 GS mutation, which may lead to a better under-
standing of not only the physiologic functions of LRRK2,
but also the potential pathologic mechanisms underlying
LRRK2 GS-associated PD.
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